These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 33563773)

  • 1. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
    Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma.
    Jang YJ; Kim EJ; Kim HD; Kim KP; Ryu MH; Park SR; Choi WM; Lee D; Choi J; Shim JH; Kim KM; Lim YS; Lee HC; Ryoo BY; Yoo C
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7547-7555. PubMed ID: 36971796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.
    Melero I; Yau T; Kang YK; Kim TY; Santoro A; Sangro B; Kudo M; Hou MM; Matilla A; Tovoli F; Knox J; He AR; El-Rayes B; Acosta-Rivera M; Lim HY; Soleymani S; Yao J; Neely J; Tschaika M; Hsu C; El-Khoueiry AB
    Ann Oncol; 2024 Jun; 35(6):537-548. PubMed ID: 38844309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
    Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
    Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
    Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study.
    Roessler D; Öcal O; Philipp AB; Markwardt D; Munker S; Mayerle J; Jochheim LS; Hammer K; Lange CM; Geier A; Seidensticker M; Reiter FP; De Toni EN; Ben Khaled N
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3065-3073. PubMed ID: 35864269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
    Gul A; Stewart TF; Mantia CM; Shah NJ; Gatof ES; Long Y; Allman KD; Ornstein MC; Hammers HJ; McDermott DF; Atkins MB; Hurwitz M; Rini BI
    J Clin Oncol; 2020 Sep; 38(27):3088-3094. PubMed ID: 32491962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer.
    Patel SP; Guadarrama E; Chae YK; Dennis MJ; Powers BC; Liao CY; Ferri WA; George TJ; Sharon E; Ryan CW; Othus M; Lopez G; Blanke CD; Kurzrock R
    Cancer; 2024 Sep; 130(17):2918-2927. PubMed ID: 38358334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study.
    Ning T; Li D; Deng T; Bai Y; Chen Y; Wang Z; Hu B; Ba Y; Lu W
    Cancer; 2024 Sep; 130(18):3137-3146. PubMed ID: 38781433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort.
    Patel SP; Othus M; Chae YK; Huynh T; Tan B; Kuzel T; McLeod C; Lopez G; Chen HX; Sharon E; Streicher H; Ryan CW; Blanke C; Kurzrock R
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39067873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
    Sangro B; Melero I; Wadhawan S; Finn RS; Abou-Alfa GK; Cheng AL; Yau T; Furuse J; Park JW; Boyd Z; Tang HT; Shen Y; Tschaika M; Neely J; El-Khoueiry A
    J Hepatol; 2020 Dec; 73(6):1460-1469. PubMed ID: 32710922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis.
    Chen X; Xu Z; Wu C; Xie L; Wang P; Liu X
    Front Immunol; 2024; 15():1255577. PubMed ID: 38390328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib.
    Tsang J; Wong JSL; Kwok GGW; Li BCW; Leung R; Chiu J; Cheung TT; Yau T
    Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):589-598. PubMed ID: 33666530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition.
    Swed B; Ryan K; Gandarilla O; Shah MA; Brar G
    Medicine (Baltimore); 2021 Jun; 100(25):e26471. PubMed ID: 34160456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
    Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV
    Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
    Kudo M; Matilla A; Santoro A; Melero I; Gracián AC; Acosta-Rivera M; Choo SP; El-Khoueiry AB; Kuromatsu R; El-Rayes B; Numata K; Itoh Y; Di Costanzo F; Crysler O; Reig M; Shen Y; Neely J; Tschaika M; Wisniewski T; Sangro B
    J Hepatol; 2021 Sep; 75(3):600-609. PubMed ID: 34051329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.
    Pinato DJ; Cortellini A; Sukumaran A; Cole T; Pai M; Habib N; Spalding D; Sodergren MH; Martinez M; Dhillon T; Tait P; Thomas R; Ward C; Kocher H; Yip V; Slater S; Sharma R
    BMC Cancer; 2021 Mar; 21(1):301. PubMed ID: 33757459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.
    Gubens MA; Sequist LV; Stevenson JP; Powell SF; Villaruz LC; Gadgeel SM; Langer CJ; Patnaik A; Borghaei H; Jalal SI; Fiore J; Saraf S; Raftopoulos H; Gandhi L
    Lung Cancer; 2019 Apr; 130():59-66. PubMed ID: 30885353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.
    Janssen JC; van Dijk B; de Joode K; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; van den Eertwegh AJM; de Groot JWB; Jalving M; de Jonge MJA; Joosse A; Kapiteijn E; Kamphuis-Huismans AM; Naipal KAT; Piersma D; Rikhof B; Westgeest HM; Vreugdenhil G; Oomen-de Hoop E; Mulder EEAP; van der Veldt AAM
    BMC Cancer; 2024 May; 24(1):632. PubMed ID: 38783238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.